Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis

Abstract Background and aims Interstitial pneumonitis is a potentially fatal complication of cancer-related therapy. However, data regarding the risk factors, prognosis and safety and benefit of rechallenge treatment are scarce. Methods Patients diagnosed with pancreatic cancer were retrospectively...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Hung-Yuan Yu, Chun-Yang Lee, Yen-Chi Hu, Le-Gin Lin, Yee Chao, Chung-Pin Li
Format: Article
Language:English
Published: BMC 2025-03-01
Subjects:
Interstitial pneumonitis
Rechallenge
Pancreatic cancer
Nab-paclitaxel
Gemcitabine
Erlotinib
Online Access:https://doi.org/10.1186/s12885-025-13896-5

Internet

https://doi.org/10.1186/s12885-025-13896-5

Similar Items